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PERSPECTIVES IN CLINICAL NEPHROLOGY
Renal manifestations of hepatitis C virus infection
The existence of viral hepatitis has been known for centuries. In
the 5th century B.C. Hippocrates noted epidemics of a jaundice-
like illness. These were particularly common during various
military campaigns, and likely represents one of the earliest
reports of "infectious hepatitis" due to hepatitis A virus, an illness
passed by fecal-oral route as a consequence of poor sanitation.
The observation in the late 1800's that hepatitis could develop
after smallpox vaccination with human lymph [1] and in the 1940's
that hepatitis could be passed by transfusion to volunteers [2] led
to the realization that there was a second type of hepatitis (that is,
"serum" hepatitis) spread by contaminated blood products. Fol-
lowing the discovery of the "Australia" antigen (hepatitis B
surface antigen, HBsAg) by Blumberg, Alter and Visnich in 1964
[3], it was recognized that many of the cases of "serum" hepatitis
were due to infection with hepatitis B virus (HBV) [4], and that
HBV was also an important cause of chronic active hepatitis and
cirrhosis [reviewed in 5]. Unfortunately, by the late 1970s it was
apparent that HBV was not the only cause of "serum" hepatitis,
and that other "non-A-non-B" hepatitis viruses existed [6], which
could be transmitted by blood products to humans and chimpan-
zees [7]. Using molecular biologic methods, Houghton and col-
leagues cloned and expressed portions of a RNA virus from the
plasma of an infected chimpanzee in 1989 [8, 9]. This virus,
designated hepatitis C virus (HCV), is now known to be a major
cause of both transfusion-associated and sporadic non-A-non-B
hepatitis [10, 11]. Infection with this virus is often persistent, and
may result in chronic active hepatitis, cirrhosis or hepatocellular
carcinoma [10—12, and reviewed in 13].
The persistent and indolent nature of HCV infection often
results in prolonged viremia in spite of a strong humoral immune
response [reviewed in 13, 14]. It is perhaps not surprising, then,
that chronic immune complex diseases may occur in this setting.
The relationship between immune complex disease of the kidney
and hepatitis B infection, a long appreciated connection, has been
recently reviewed [15]. In this paper, we will discuss some of the
more recently recognized extrahepatic manifestations of HCV
infection, with particular emphasis on its association with glomer-
ular disease.
Biology, clinical features, diagnosis and epidemiology of HCV
virus
HCV is a lipid enveloped, single stranded, positive-sense RNA
virus in the family Flaviviridae, which also includes the flaviviruses
(such as, yellow fever and dengue viruses) and pestiviruses (such
as, hog cholera virus) [reviewed in 13, 14]. The HCV genome is
approximately 9600 nucleotides in length and contains a single
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open reading frame that encodes a 3010 amino acid polyprotein
that undergoes proteolytic processing to form structural and
nonstructural viral proteins (Fig. 1). At the 5' end is a highly
conserved untranslated region, followed by the nucleocapsid
domain which encodes the core antigen (c22-3), a region coding
for at least two envelope glycoprotein antigens (El and E2INS1),
and a region encoding at least four nonstructural gene products
(NS2-NS5). The functions of the nonstructural proteins are not
completely elucidated, but it is believed that NS2 codes for a
protease, NS3 likely encodes helicase (involved in unraveling the
RNA genome for replication), NS4 codes for a putative RNA
binding protein, and NS5 codes for the RNA-dependent RNA
polymerase [14]. Significant nucleotide and amino acid heteroge-
neity is present throughout the HCV genome, with a well-
characterized hypervariable region in the E2 envelope glycopro-
tein domain [16]. This has led to the recognition of at least six
HCV subtypes based on differences in the nucleotide sequence for
NS5 [17].
HCV infection may be transmitted by blood products or as a
consequence of intravenous drug abuse [13]. Transmission by
sexual contact or by vertical transmission from mother to infant
likely occurs but appears to be infrequent [13]. In as many as 20
to 40% of cases, no known risk factor for HCV infection can be
found [13].
Infection is followed by an incubation period of 6 to 12 weeks
prior to the development of clinical hepatitis. In the majority of
cases the hepatitis is mild and anicteric. Persistent viremia despite
resolution of the acute hepatitis is seen in the majority of cases.
Although many of these patients have persistent viremia despite
minimal liver pathology, suggesting the presence of a "healthy"
carrier state, at least 50% of patients develop chronic hepatitis, of
which 20% progress to cirrhosis or chronic active hepatitis [13].
Epidemiologic studies suggest that HCV infection may also be an
important cause of hepatocellular carcinoma [12].
Serologic assays are routinely used to diagnose HCV infection.
The original first generation enzyme immunoassay (EIA-l), which
measured antibodies to the nonstructural Cl00-3 antigen (coded
by the NS4 domain), lacked sensitivity and specificity, and was
undetectable in 10 to 25% of patients with chronic HCV viremia
and falsely present in both healthy individuals and patients with
chronic autoimmune hepatitis [18, 19]. The second generation
enzyme immunoassay (EIA-2) measures antibodies to recombi-
nant core and NS3 antigens in addition to that coded by NS4, and
has greatly improved sensitivity (—95%) and specificity. A sup-
plemental serologic assay, the recombinant immunoblot assay
(RIBA II test), measures antibody to four HCV antigens (the
nonstructural antigens 5-1-1, C100-3, and C33, and the core
antigen C22), and has comparable sensitivity and slightly more
specificity than the EIA-2 test [13]. However, diagnosis of acute
HCV infection by measuring anti-HCV antibodies is compro-
mised by the fact that the humoral response is often delayed.
Indeed, both IgG and 1gM antibodies to HCV antigens may not
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histologically resembles SjOgren's syndrome [55]. Other syn-
dromes possibly associated with chronic HCV infection include
chronic corneal ulcerations (that is, Mooren's ulcer) [56], porphy-
ria cutanea tarda [57], lichen planus [58], autoimmune thyroiditis
[59], and polyarteritis nodosa [60, 61]. There may also be an
increased risk for lymphoproliferative disorders characterized by
monoclonal gammopathy with chronic HCV infection [38, 39, and
unpublished observations]. The rest of the discussion will concen-
trate on the associations of HCV infection with cryoglobulinemia
and glomerulonephritis.
Mixed ciyoglobulinemia and HCV infection
Fig. 1. HCVgenome. The HCV genome consists of a single open reading
frame with a 5' conserved region, and regions encoding the nucleocapsid
(core), several envelope antigens (envi and env2/NS1) and several non-
structural proteins (NS2-NS5). Assays to detect HCV infection include the
first and second generation enzyme immunoassays (EIA4 and EIA-2,
respectively) and the recombinant immunoblot assay (RIBA) which detect
antibodies to various recombinant antigens derived from the HCV
genome. A reverse transcriptase polymerase chain reaction (RT-PCR)
assay using primers to the 5' conserved region is used to detect HCV RNA
and is the best test to determine infectivity.
occur until 2 to 12 months following infection (that is, after the
clinical episode of hepatitis) [13, 20], and delayed or absent
seroconversion may develop in the setting of immunosuppression
or viral mutation. The most definitive test for diagnosing active
HCV infection is the reverse transcription polymerase chain
reaction (RT-PCR), which measures the presence of viral RNA in
patient serum and hence determines potential infectivity [13, 21].
The vast majority of individuals with HCV infection test contin-
uously positive by RT-PCR for periods of 20 years or longer, and
spontaneous resolution of HCV viremia is unusual. Although
RT-PCR is technically difficult, expensive and often problematic
[22], an accurate, standardized assay is available from several
reference laboratories [21, 23].
Epidemiologic studies have shown that chronic HCV infection
affects 0.3% of the population of Canada and Northern Europe,
0.6% of the United States and Central Europe, 1.2 to 1.5% of
Japan and Southern Europe, and 3.5 to 6.4% in some regions of
Africa [24—26]. Interestingly, in Peru HCV infection appears to be
extremely rare [27]. In high risk groups the prevalence of HCV
infection is higher, being 60 to 90% of hemophiliacs, 60 to 70% of
intravenous drug abusers, 15 to 25% of dialysis patients, and 4 to
8% of homosexual men [13, 241. However, the incidence of
post-transfusion HCV infection in the United States is decreasing;
this is due in part to the screening of blood in blood banks in the
1980's for "surrogate" markers for HCV infection (such as
elevated alanine aminotransferase levels or the presence of anti-
HBc antibodies [28, 29]), and more recently by the screening of
donor blood for specific anti-HCV antibodies [30], as well as by
the avoidance of blood donation from high risk groups.
Extrahepatic manifestations of HCV infection
Recently, several extrahepatic syndromes have been reported
with chronic HCV infection. These include the mixed cryoglobu-
linemias [31—44], niembranoproliferative glomerulonephritis
(MPGN) [31, 45—53], arthritis [54] and a sicca syndrome that
Cryoglobulins are immunoglobulins that will precipitate in the
cold, and are classified as type I if the cryoprecipitates contain a
single monoclonal antibody (such as in myeloma or Walden-
strom's macroglobulinemia), type II if they contain polyclonal IgG
and a monoclonal 1gM, and type III if they contain polyclonal IgG
and polyclonal 1gM. In the "mixed cryoglobulinemias" (that is,
types II and III) the 1gM typically has rheumatoid factor activity
(that is, anti-IgG activity).
Mixed cryoglobulinemias have been previously associated with
connective tissue diseases (especially Sjogren's syndrome), infec-
tions, malignancies and chronic liver disease [62—66]. If no
underlying association could be found, mixed cryoglobulinemia
was labeled "essential." Clinical manifestations of mixed cryo-
globulinemia are often chronic, and include palpable purpura
(from a leukocytoclastic vasculitis), Raynaud's phenomenon, leg
ulcers, arthralgias and/or arthritis, and peripheral neuropathy
[62—66]. Seventy percent have abnormal liver function tests, and
in severe cases cardiomyopathy or abdominal pain requiring
laparotomy may develop [66]. The development of renal disease,
which occurs in half of the cases, carries the worst prognosis [66].
The principal glomerular lesion is membranoproliferative glomer-
ulonephritis, but diffuse, focal or mesangial proliferative glomer-
ulonephritis has also been reported, especially in association with
type III mixed cryoglobulinemia [66—72]. Occasional patients may
also have granulomatous vasculitis of small and moderately sized
renal arteries [66, 67].
Levo et al were the first to suggest that mixed cryoglobulinemia
was a manifestation of chronic HBV infection [64, 65]. Two-thirds
of patients with essential mixed cryoglobulinemia have abnormal
liver function, and as many as 50% of patients had antibodies to
the HBsAg in their blood [64, 65]. When the cryoprecipitates were
examined, 74% were positive either for the HBsAg or anti-HBs
[64]. However, the association of cryoglobulinemia with HBV
infection could not be confirmed in another study [63]. The
frequency of liver function abnormalities was also independent of
the HBV status [64, 66]. These data were consistent with the
hypothesis that a different hepatic virus was involved in the
pathogenesis of the cryoglobulinemia.
It is now apparent that HCV is the major cause of mixed
cryoglobulinemia. HCV RNA (as detected by RT-PCR) and HCV
antibodies (as detected by EIA-2 or RIBA-2) are present in the
serum of the majority (>80%) of patients with mixed cryoglobu-
linemia [32, 33, 39-44]. In these patients, HCV RNA and
anti-HCV antibody have been shown to be concentrated in the
cryoprecipitates [41—46]. In some of the cryoprecipitates, the
monoclonal 1gM appears to have a stronger binding affinity for
antibody to the HCV core antigen (C22) than to control IgG [45].
While these data suggest an important role for HCV infection in
cryoglobulinemia, other viruses, such as HBV [64] or Epstein-
Barr virus [73] may also be involved in some cases.
Glomerulonephritis
Background. Glomerular disease often accompanies chronic
liver disease, although frequently it is clinically silent [74—83]. In
addition to cryoglobulinemic MPGN, mesangial proliferative,
membranoproliferative, membranous, diffuse proliferative, and
sclerosing glomerulonephritis (ON) also have been reported
[78—83]. A mesangial proliferative ON with IgA deposition is
especially common [79, 82].
Although these glomerular diseases may occur in association
with a wide variety of liver diseases [78—81], patients with chronic
HBV infection are particularly predisposed to develop membra-
nous and membranoproliferative ON [reviewed in 15]. These
diseases are thought to be mediated by HBeAg and HBsAg
immune complexes, respectively, although other pathogenic
mechanisms have not been entirely excluded [15].
Several studies have documented an association of chronic
HCV infection with MPGN [31, 45—53]. We have now studied the
clinical and virologic features of 35 of these patients (manuscript
submitted).
Clinical and laboratory features. Patients presented with ne-
phrotic syndrome or occasionally with non-nephrotic proteinuria
and mild to moderate renal insufficiency. Whereas many of these
patients have type II, or, more rarely, type III cryoglobulinemia
[31, 45—51], 30 to 40% do not have detectable circulating cryo-
globulins at presentation [45, and manuscript submitted]. Indeed,
symptoms suggestive of cryoglobulinemia, such as purpura, arthri-
tis, or neuropathy, were present in only one-half of HCV-infected
patients with MPON. In addition, only 20% of patients had
physical signs of liver disease, although the majority (60 to 70%)
have mildly elevated transaminases. Other laboratory features
of HCV-associated MPGN include hypocomplementemia (de-
pressed CH5O, C4, and often C3), the presence of rheumatoid
factors, and elevated Clq binding. Tests for antinuclear and
anti-neutrophil cytoplasmic antibodies were generally negative.
Pathology. Renal biopsy typically shows an increased cellularity
and accentuation of the lobular architecture of the glomerular
tuft, often with double contours of the basement membrane noted
by silver methenamine staining [45] (Fig. 2). Mesangial prolifer-
ation and sclerosis may also be present. By immunofluorescence,
mesangial and capillary wall deposition of 1gM, IgO, and C3 can
be demonstrated in most cases, although the deposition may be
modest, and in as many as one-third of cases no or only trace IgG
is found. Electron microscopy usually shows subendothelial de-
posits characteristic of MPGN type I, although mesangial and
subepithelial immune deposits are occasionally observed. In some
cases the immune deposits have ultrastructural features of cryo-
globulins such as granular, finely fibrillar, or immunotactoid
structures. In addition to the glomerular disease, tubulointerstitial
inflammation and scarring are common, and in two cases we have
noted vasculitis of small and medium sized renal arteries.
Although the classic lesion is usually cryoglobulinemic or
noncryoglobulinemic MPON type I, the occasional presence of
subepithelial immune deposits may suggest a pattern of injury that
has been called MPON type III, and the relative lack of immune
deposits occasionally observed is similar to some cases of acute
exudative and proliferative ON. Areas of focal sclerosis may also
be prominent.
Fig. 2. HCV-associated MPGN. A By light microscopy, glomeruli display
hypercellularity in a lobular pattern. B Immunofluorescence shows capil-
laiy wall deposition of 1gM, often with IgG and C3. C Electron microscopy
usually shows immune deposits in the subendothelial and paramesangial
spaces (arrows).
HCV-associated MPGN may also develop following liver [52]
or renal transplantation. We have observed a proliferative gb-
merulopathy with histologic features similar to MPON or trans-
plant gbomerulopathy in two renal transplant patients with HCV
infection (manuscript in preparation). Both patients had
nephrotic range proteinuria, a rising serum creatinine, mildly
elevated liver function tests, hypocomplementemia, circulating
rheumatoid factors, and serum that was positive for HCV RNA
and antibody. One patient had cryogbobulinemia, whereas the
other had circulating immune complexes as detected by an
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elevated Clq binding test. Biopsy in both cases showed a mem-
branoproliferative lesion with 1gM and C3 deposition, but no or
only trace amounts of IgG, and with occasional subendothelial
immune deposits by electron microscopy. These findings are
consistent with MPGN, but are not clearly distinguishable from
allograft glomerulopathy [84].
Virology. Evidence suggesting a causative role for HCV infec-
tion in the development of MPON has been based on the
demonstration of HCV RNA and antibody in the serum, and, in
those cases where cryoprecipitates were available, to demonstrate
the concentration of the HCV RNA and antibody in the cryo-
globulins [45—53]. Furthermore, immune complexes and cryo-
globulins have been localized within glomeruli in the subendothe-
hal space of the capillary walls. However, identification of the
virus in the glomeruli has remained elusive, although one report
claims to show virus-like particles in the mesangium [47]. Further
evidence for a viral etiology may be provided as more effective
methods for detecting HCV antigens and RNA in tissue become
available [85—88].
How important is HCVas an etiologic factor for MPGN? Recent
evidence suggests that HCV infection may be an important cause
of MPON, especially in countries where HCV infection is highly
prevalent. For example, in Northern Japan, HCV infection was
noted in 6 of 10 random patients (60%) with MPGN, in one study,
whereas it was present in only 1 of 58 patients with IgA nephrop-
athy and in 0 of 12 patients with minimal change disease [51]. We
found HCV RNA and antibody in 2 of 10 random patients with
MPON type I [45], but our impression is that it may be signifi-
cantly more common than this initial sampling suggests. Indeed,
one wonders if the decline in MPGN observed in Europe and
North America in the 1970s and 1980's [89—91, and Daniel
Cattran, personal communication] reflects the policies of some
blood banks to exclude blood with "surrogate" markers of HCV
infection, such as the presence of elevated transaminase activity or
of anti-HBc antibody [28, 29]. One may also speculate that the
high incidence of MPGN observed in some developing countries,
such as in Ethiopia [92] may relate to the relatively high preva-
lence of HCV infection in these areas [25, 26].
Other types of GN. The primary glomerular lesion associated
with HCV infection is cryoglobulinemic or noncryoglobulinemic
MPGN. However, as noted above, the lesion may also appear as
an acute exudative and proliferative nephritis, MPGN type III, or,
in transplant patients, as a lesion indistinguishable from allograft
glomerulopathy. We have also noted six cases of HCV infection
associated with membranous nephropathy (unpublished data),
and several cases of HCV infection and membranous ON have
been reported by others [93, 94]. These cases clinically present
like classic idiopathic membranous nephropathy, and patients
have normal complement levels, an absence of rheumatoid factor
or cryoglobulinemia, and often normal liver function. The obser-
vation in one study that 8% of patients with membranous
nephropathy in Northern Japan had HCV antibodies and HCV
RNA as compared to less than 1% of patients with other types of
ON (but excluding MPGN) suggests that this association is not
strong but may well be significant [51].
Pathogenesis
The pathogenesis of HCV-associated ON likely relates to the
glomerular deposition of circulating immune complexes contain-
ing HCV antigens, anti-HCV antibodies, and rheumatoid factors
(anti-IgG antibodies). Circulating HCV and anti-HCV immune
complexes should occur in most HCV-infected patients as viremia
is usually persistent despite a strong antibody response [12, 13].
We [45] and others [41, 42] have demonstrated that HCV RNA is
concentrated over 100-fold relative to serum in the cryoprecipi-
tates of our patients with HCV-associated cryoglobulinemia or
MPGN. The lack of a neutralizing antibody response to HCV may
relate to the ability of the HCV virus to change its envelope
antigens by mutation during the course of infection [95]. This
would result in spontaneous changes in antibody affinity and
avidity, and could potentially explain the chronic relapsing course
frequently observed in untreated patients with mixed cryoglobu-
linemia [66, 96].
The mechanism for the development of an 1gM rheumatoid
factor in these patients remains unclear. In those patients with
type II cryoglobulinemia, the monoclonal 1gM can frequently be
shown to be a specific serologically-defined rheumatoid factor
cross-reactive idiotype termed WA [41], which is believed to be
encoded by germline genes [97, 98]. Although the 1gM antibody
frequently binds to normal pooled IgG, several of our patients had
1gM which appeared to bind more avidly to anti-HCV core (C22)
IgO than nonspecific human IgG [45]. This raises the question as
to whether the 1gM rheumatoid factor may bind preferentially to
anti-HCV IgG or to the IgG-HCV immune complex. Indeed, it
has been reported that the 1gM rheumatoid factors in patients
with mixed cryoglobulinemia have anti-idiotypic activity against
homologous IgO [99]. If the 1gM anti-IgG activity were induced
by the persistently elevated anti-HCV IgG in predisposed pa-
tients, then the binding of this 1gM to HCV-IgG immune com-
plexes would potentiate immune complex formation and deposi-
tion, possibly resulting in a clinical presentation of either mixed
cryoglobuhinemia or MPGN.
Evidence supports the hypothesis that the circulating immune
complexes localize to the glomerular capillaries where they de-
posit in the subendothelium and mesangium and initiate local
cellular proliferation and leukocyte inifitration [45]. The variabil-
ity in degree of immune deposits observed may be due to the
balance between deposition and normal mechanisms of clearance.
For example, it is known experimentally that, whereas immune
complexes may persist in the subendothelial space [100], in some
conditions it may be rapidly cleared from the glomerular suben-
dothehium [101]. Studies of leukocytoclastic vasculitis in man have
also shown that immune deposits are cleared from the subendo-
thelial space of the dermal capillaries within 24 to 48 hours [102].
Two alternative hypotheses should also be considered. First, it
is now recognized that chronic HCV infection may result in
autoantibody formation, such as anti-GOR antibodies (directed to
a host-derived nuclear antigen [103]), type 1 liver-kidney micro-
somal antibodies, anti-smooth muscle antibodies, antinuclear
antibodies, and occasionally perinuclear anti-neutrophil cytoplas-
mic antibodies (P-ANCA) [58, 104, 105]. It is possible that
autoantibodies to native renal antigens may also develop that
could account for some of the glomerular pathology. Second, the
observation that MPGN may occur in patients with HBV-negative
and HCV-negative liver disease [81] suggests that chronic liver
disease, perhaps via the impaired clearance of immune complexes,
may contribute to the pathogenesis of MPGN directly.
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Treatment and management
Alpha interferon
Alpha interferon (a-IFN) is currently approved in the United
States for the treatment of chronic HCV infection. Treatment
with a-IFN (2 to 3 million U three times per week for 6 months)
suppresses viremia and improves liver function and histology in
50% of patients with chronic HCV infection [106, 107]. Unfortu-
nately, clinical relapses occur in at least 50% of patients after
completing treatment [106, 107].
Given its ability to inhibit HCV viral replication, a-IFN could
potentially be useful in the treatment of extrahepatic manifesta-
tions of HCV infection, such as mixed cryoglobulinemia or
MPGN. Indeed, a-IFN has been used to treat patients with
essential mixed cryoglobulinemia [37, 108—114] and MPGN [45,
and manuscript submitted]. In patients with cryoglobulinemia,
a-IFN improves the clinical symptoms such as the purpura and
arthralgias, and reduces the cryoglobulin levels in the majority of
patients [37, 108—113]. However, clinical relapse is common after
therapy is stopped [108—113].
Recently Misiani et al have reported the effect of a-IFN in 25
patients with HCV-associated mixed cryoglobulinemia, of which
about three quarters had renal involvement [114]. Sixty percent
(N = 15) became negative in their serum for HCV RNA by
RT-PCR during therapy, and it was these patients who had
significant improvements in cutaneous vasculitis, as well as signif-
icant decreases in ciyoglobulins, rheumatoid factor and serum
creatinine. Unfortunately, viremia and cryoglobulinemia recurred
in all HCV RNA-negative patients after therapy was discontinued
[114].
We have treated 17 American patients with both cryoglobuline-
mic and non-cryoglobulinemic HCV-associated MPGN with
a-IFN, of which 14 have been treated for 6 months or longer
(manuscript in press). Treatment was associated with a significant
reduction (65%) in proteinuria, and normalization of liver func-
tion tests, but with no significant change in renal function. As with
the study of Misiani et al [114], a good clinical response correlated
with disappearance of HCV RNA from the blood as measured by
RT-PCR, however, relapse of viremia and renal disease were
common after completing therapy. This suggests that future
protocols using a-IFN may need to consider higher doses or
longer duration of therapy.
Side effects of a-IFN have included flu-like symptoms, insom-
nia, and malaise. Two patients have developed erythema multi-
form requiring discontinuation of therapy. A reduction in diuretic
dosage is often required in the first month. Rare patients with
cryoglobulinemia have had transient worsening of pre-existent
peripheral neuropathies [110, 113, and unpublished observations].
This may relate to the ability of a-IFN to up-regulate class I and
II antigens and to augment the immunologic response [115].
Although a-IFN has been reported to occasionally induce pro-
teinuria [116, 117], we have not observed worsening proteinuria in
any of our patients.
Immunosuppressive therapies
What is the role for immunosuppressive therapy in the man-
agement of extrahepatic HCV disease? Because of the waxing and
waning nature of essential mixed ciyoglobulinemia and cryoglobu-
linemic GN, some investigators have suggested that no treatment
is necessary unless the renal disease is progressive [reviewed in 66,
67, 96]. However, in situations where the clinical manifestations
are severe, immunosuppressive treatment with steroids, cytotoxic
agents (that is, cyclophosphamide or chlorambucil), and/or plas-
mapheresis has been frequently recommended [reviewed in 66,
67, 96]. Unfortunately, most reports of beneficial responses have
been anecdotal, and relapses are common [66, 67]. However,
there is evidence that pulse methylprednisolone therapy may
significantly improve renal function in these patients, but most
patients remain with significant proteinuria and low levels of
circulating cryoglobulins [118].
We have not observed any spontaneous remissions of renal
disease in our patients with HCV-associated MPGN, and patients
have either remained stable or progressed over a 6 month period.
We have also not observed any reduction in proteinuria in five
patients who received various doses of oral corticosteroids, a!-
though it did appear to improve the skin lesions in the two
patients who had purpura. The administration of "pulse" steroids
has resulted in improved renal function in two of our patients,
although both have remained HCV RNA positive. We have also
had five patients that received prednisone and cyclophosphamide
with or without plasma exchange. Three of these patients, how-
ever, subsequently died from infectious complications, which are
known to be associated with this type of therapy [119]. We are
aware of one additional patient with HCV-associated MPGN who
had a complete remission with prednisone and cyclophosphamide;
however, serial blood samples during therapy also showed a rapid
increase in HCV RNA as determined by quantitative PCR (Quigg
R, Gretch DR, unpublished observations).
Based on knowledge of other chronic viral infections, it is likely
that cell mediated immunity plays an important role in controlling
HCV infection. HCV-specific CD8+ lymphocytes can be identi-
fied in livers of infected chimpanzees and humans [120, 121]. Of
potentially greater significance, it has been shown that CD4+ T
lymphocytes proliferate in response to the HCV core antigen, and
that the T cell proliferative response is associated with a benign
hepatic course [122]. Milder liver disease is also associated with
less HCV viremia relative to that observed in patients with
advanced liver disease [123, 124]. This suggests that the T cell
response can be correlated both with the degree of viremia and
the severity of liver disease.
In circumstances where the T cell response to HCVis impaired,
as with immunosuppressive therapy, one might expect to see
increased HCV viremia and worsening of liver disease. In most
liver transplant recipients HCV viremia recurs [125], and viral
RNA titers increase rapidly (D. Gretch, manuscript submitted). In
as many as 50% of liver transplant patients this is followed by
recurrent liver disease within one year of transplant [126 and DG,
manuscript submitted]. Nonetheless, although HCV is a major
cause of post-transplant hepatitis, many HCV-infected patients
have a benign course following transplantation (at least in the
initial but often relatively short follow-up period) [127—131].
However, in some cases advanced liver disease may develop [127,
129]. One variable that appears to correlate with the development
of liver disease in these patients is the cumulative dose of
anti-lymphoblast globulin administered [130].
If immunosuppressive medication is detrimental, then why do
some patients do well without evidence for worsening liver
disease? One possibility is that immunosuppressive therapy may
not be able to impair a strong CD4+ response to HCV core
antigen if it is already present. In contrast, if the CD4+ response
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was weak, such that the patient already had evidence of significant
viremia and liver disease, then the immunosuppression may be
enough to lead to a rapid increase in the viremia. This is
consistent with recent observations that the risk for progressive
liver disease in renal transplant patients is much greater if the
pre-transplant liver biopsy shows chronic liver disease [132]. The
degree of histocompatibility is also likely important, as recent
studies in HCV-infected liver transplant patients suggest that the
risk for development of progressive liver disease is greater if the
donor and recipient are matched at the HLA-DQI3 locus [133].
Conclusion
HCV is a major cause of chronic liver disease, but it is also
associated with extrahepatic manifestations, including mixed cryo-
globulinemia and glomerulonephritis. The principal type of gb-
merulonephritis observed is either a cryoglobulinemic-type of
MPGN, or MPGN type I. Initial epidemiologic studies suggest
that HCV infection may be a major cause of both types of
glomerulonephritis. Patients with glomerulonephritis may have no
clinical evidence for systemic or liver involvement, and liver
function tests may be normal. These patients usually have hypo-
complementemia, circulating rheumatoid factors, and in two-
thirds of cases, cryoglobulinemia. The pathogenesis of HCV-
associated MPGN is likely to be mediated by the glomerular
deposition of circulating HCV and anti-HCV antibodies. Treat-
ment with a-interferon may be of benefit in suppressing the
viremia, reducing the proteinuria and stabilizing the renal func-
tion, but long term and controlled studies are needed to prove this
and to assess the risk for relapse. Although immunosuppressive
treatment has been commonly used to treat mixed cryogbobuline-
mia and MPGN in the past, a re-evaluation of the effects of this
treatment on HCV viremia and antibody response, and on the
liver and renal disease is indicated.
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